ID   MCA2_TRYB2              Reviewed;         347 AA.
AC   Q585F3; D6XHH8;
DT   07-OCT-2020, integrated into UniProtKB/Swiss-Prot.
DT   10-MAY-2005, sequence version 1.
DT   07-APR-2021, entry version 94.
DE   RecName: Full=Metacaspase-2 {ECO:0000305};
DE            EC=3.4.22.- {ECO:0000269|PubMed:18005666, ECO:0000269|PubMed:22529389, ECO:0000269|PubMed:23506317, ECO:0000269|PubMed:28089596};
DE   AltName: Full=TbMCA2 {ECO:0000303|PubMed:23506317};
DE   Contains:
DE     RecName: Full=Large subunit p20 {ECO:0000305};
DE   Contains:
DE     RecName: Full=Small subunit p10 {ECO:0000305};
DE   Flags: Precursor;
GN   Name=MCA2 {ECO:0000303|PubMed:18005666};
GN   ORFNames=Tb927.6.940 {ECO:0000312|EMBL:AAX80349.1};
OS   Trypanosoma brucei brucei (strain 927/4 GUTat10.1).
OC   Eukaryota; Discoba; Euglenozoa; Kinetoplastea; Metakinetoplastina;
OC   Trypanosomatida; Trypanosomatidae; Trypanosoma.
OX   NCBI_TaxID=185431 {ECO:0000312|Proteomes:UP000008524};
RN   [1] {ECO:0000312|EMBL:AAZ11657.1}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=927/4 GUTat10.1 {ECO:0000312|EMBL:AAZ11657.1};
RX   PubMed=16020724; DOI=10.1126/science.1112181;
RA   El-Sayed N.M., Myler P.J., Blandin G., Berriman M., Crabtree J.,
RA   Aggarwal G., Caler E., Renauld H., Worthey E.A., Hertz-Fowler C.,
RA   Ghedin E., Peacock C., Bartholomeu D.C., Haas B.J., Tran A.N.,
RA   Wortman J.R., Alsmark U.C., Angiuoli S., Anupama A., Badger J.,
RA   Bringaud F., Cadag E., Carlton J.M., Cerqueira G.C., Creasy T.,
RA   Delcher A.L., Djikeng A., Embley T.M., Hauser C., Ivens A.C.,
RA   Kummerfeld S.K., Pereira-Leal J.B., Nilsson D., Peterson J., Salzberg S.L.,
RA   Shallom J., Silva J.C., Sundaram J., Westenberger S., White O.,
RA   Melville S.E., Donelson J.E., Andersson B., Stuart K.D., Hall N.;
RT   "Comparative genomics of trypanosomatid parasitic protozoa.";
RL   Science 309:404-409(2005).
RN   [2] {ECO:0000312|Proteomes:UP000008524}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=927/4 GUTat10.1 {ECO:0000312|Proteomes:UP000008524};
RX   PubMed=16020726; DOI=10.1126/science.1112642;
RA   Berriman M., Ghedin E., Hertz-Fowler C., Blandin G., Renauld H.,
RA   Bartholomeu D.C., Lennard N.J., Caler E., Hamlin N.E., Haas B., Bohme U.,
RA   Hannick L., Aslett M.A., Shallom J., Marcello L., Hou L., Wickstead B.,
RA   Alsmark U.C.M., Arrowsmith C., Atkin R.J., Barron A.J., Bringaud F.,
RA   Brooks K., Carrington M., Cherevach I., Chillingworth T.J., Churcher C.,
RA   Clark L.N., Corton C.H., Cronin A., Davies R.M., Doggett J., Djikeng A.,
RA   Feldblyum T., Field M.C., Fraser A., Goodhead I., Hance Z., Harper D.,
RA   Harris B.R., Hauser H., Hostetler J., Ivens A., Jagels K., Johnson D.,
RA   Johnson J., Jones K., Kerhornou A.X., Koo H., Larke N., Landfear S.,
RA   Larkin C., Leech V., Line A., Lord A., Macleod A., Mooney P.J., Moule S.,
RA   Martin D.M., Morgan G.W., Mungall K., Norbertczak H., Ormond D., Pai G.,
RA   Peacock C.S., Peterson J., Quail M.A., Rabbinowitsch E., Rajandream M.A.,
RA   Reitter C., Salzberg S.L., Sanders M., Schobel S., Sharp S., Simmonds M.,
RA   Simpson A.J., Tallon L., Turner C.M., Tait A., Tivey A.R., Van Aken S.,
RA   Walker D., Wanless D., Wang S., White B., White O., Whitehead S.,
RA   Woodward J., Wortman J., Adams M.D., Embley T.M., Gull K., Ullu E.,
RA   Barry J.D., Fairlamb A.H., Opperdoes F., Barrell B.G., Donelson J.E.,
RA   Hall N., Fraser C.M., Melville S.E., El-Sayed N.M.A.;
RT   "The genome of the African trypanosome Trypanosoma brucei.";
RL   Science 309:416-422(2005).
RN   [3] {ECO:0000305}
RP   FUNCTION, CATALYTIC ACTIVITY, ACTIVITY REGULATION, PROTEOLYTIC CLEAVAGE,
RP   ACTIVE SITE, AND MUTAGENESIS OF LYS-55; CYS-212; CYS-213 AND LYS-268.
RX   PubMed=18005666; DOI=10.1016/j.febslet.2007.11.009;
RA   Moss C.X., Westrop G.D., Juliano L., Coombs G.H., Mottram J.C.;
RT   "Metacaspase 2 of Trypanosoma brucei is a calcium-dependent cysteine
RT   peptidase active without processing.";
RL   FEBS Lett. 581:5635-5639(2007).
RN   [4] {ECO:0000305}
RP   FUNCTION, CATALYTIC ACTIVITY, ACTIVITY REGULATION, BIOPHYSICOCHEMICAL
RP   PROPERTIES, AND DOMAIN.
RX   PubMed=23506317; DOI=10.1111/febs.12248;
RA   Machado M.F., Marcondes M.F., Juliano M.A., McLuskey K., Mottram J.C.,
RA   Moss C.X., Juliano L., Oliveira V.;
RT   "Substrate specificity and the effect of calcium on Trypanosoma brucei
RT   metacaspase 2.";
RL   FEBS J. 280:2608-2621(2013).
RN   [5] {ECO:0000305}
RP   CATALYTIC ACTIVITY, ACTIVITY REGULATION, BIOPHYSICOCHEMICAL PROPERTIES,
RP   PROTEOLYTIC CLEAVAGE, AND MUTAGENESIS OF LYS-55 AND LYS-268.
RX   PubMed=28089596; DOI=10.1016/j.bbapap.2017.01.002;
RA   Gilio J.M., Marcondes M.F., Ferrari D., Juliano M.A., Juliano L.,
RA   Oliveira V., Machado M.F.M.;
RT   "Processing of metacaspase 2 from Trypanosoma brucei (TbMCA2) broadens its
RT   substrate specificity.";
RL   Biochim. Biophys. Acta 1865:388-394(2017).
RN   [6] {ECO:0007744|PDB:4AF8, ECO:0007744|PDB:4AFP, ECO:0007744|PDB:4AFR}
RP   X-RAY CRYSTALLOGRAPHY (1.40 ANGSTROMS) OF MUTANTS GLY-213 AND ALA-213,
RP   CATALYTIC ACTIVITY, ACTIVITY REGULATION, SUBUNIT, PROTEOLYTIC CLEAVAGE, AND
RP   MUTAGENESIS OF TYR-31; CYS-92; ASP-95; SER-156; 189-ASP--ASP-190 AND
RP   ASP-211.
RX   PubMed=22529389; DOI=10.1073/pnas.1200885109;
RA   McLuskey K., Rudolf J., Proto W.R., Isaacs N.W., Coombs G.H., Moss C.X.,
RA   Mottram J.C.;
RT   "Crystal structure of a Trypanosoma brucei metacaspase.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:7469-7474(2012).
CC   -!- FUNCTION: Cysteine protease that cleaves specifically after arginine or
CC       lysine residues. {ECO:0000269|PubMed:18005666,
CC       ECO:0000269|PubMed:23506317}.
CC   -!- ACTIVITY REGULATION: Activated by Ca(2+) (PubMed:18005666,
CC       PubMed:23506317, PubMed:28089596, PubMed:22529389). In response to
CC       calcium binding, the 280-loop, a disordered loop consisting of residues
CC       269-275, undergoes a conformational change which stabilizes substrates
CC       in the active site (PubMed:22529389). The binding to the substrate
CC       triggers the release of the N-terminal region resulting in the
CC       activation of the enzyme (PubMed:22529389). Proteolytic cleavage is
CC       required for catalytic activity towards large protein substrates
CC       (PubMed:28089596). {ECO:0000269|PubMed:18005666,
CC       ECO:0000269|PubMed:22529389, ECO:0000269|PubMed:23506317,
CC       ECO:0000269|PubMed:28089596}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       pH dependence:
CC         Optimum pH is 7.7. {ECO:0000269|PubMed:23506317,
CC         ECO:0000269|PubMed:28089596};
CC       Temperature dependence:
CC         Optimum temperature is 20-25 degrees Celsius.
CC         {ECO:0000269|PubMed:23506317};
CC   -!- SUBUNIT: Monomer. {ECO:0000269|PubMed:22529389}.
CC   -!- SUBCELLULAR LOCATION: Recycling endosome
CC       {ECO:0000250|UniProtKB:Q8T8E7}.
CC   -!- DOMAIN: There are 2 calcium binding sites with high and low affinity,
CC       respectively. {ECO:0000269|PubMed:23506317}.
CC   -!- PTM: Auto-proteolytic cleavage of the propeptide after Lys-55 and
CC       between the large and small subunits after Lys-268 is required for
CC       catalytic activity towards large protein substrates but is dispensable
CC       towards small oligopeptide substrates (PubMed:18005666,
CC       PubMed:28089596, PubMed:22529389). After processing, the propeptide and
CC       the large and small subunits remain associated by non-covalent bonds
CC       (PubMed:18005666). In vivo, the unprocessed enzyme appears to be the
CC       predominant form (By similarity). {ECO:0000250|UniProtKB:Q8T8E7,
CC       ECO:0000269|PubMed:18005666, ECO:0000269|PubMed:22529389,
CC       ECO:0000269|PubMed:28089596}.
CC   -!- SIMILARITY: Belongs to the peptidase C14B family. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; CP000069; AAZ11657.1; -; Genomic_DNA.
DR   EMBL; AC073906; AAX80349.1; -; Genomic_DNA.
DR   RefSeq; XP_845216.1; XM_840123.1.
DR   PDB; 4AF8; X-ray; 1.40 A; A=1-347.
DR   PDB; 4AFP; X-ray; 2.10 A; A=1-347.
DR   PDB; 4AFR; X-ray; 1.60 A; A=1-347.
DR   PDB; 4AFV; X-ray; 1.50 A; A=1-347.
DR   PDBsum; 4AF8; -.
DR   PDBsum; 4AFP; -.
DR   PDBsum; 4AFR; -.
DR   PDBsum; 4AFV; -.
DR   SMR; Q585F3; -.
DR   STRING; 5691.AAZ11657; -.
DR   MEROPS; C14.044; -.
DR   GeneDB; Tb927.6.940:pep; -.
DR   GeneID; 3657732; -.
DR   KEGG; tbr:Tb927.6.940; -.
DR   VEuPathDB; TriTrypDB:Tb927.6.940; -.
DR   eggNOG; KOG1546; Eukaryota.
DR   OMA; WAFISAI; -.
DR   Proteomes; UP000008524; Chromosome 6.
DR   GO; GO:0005634; C:nucleus; IDA:GeneDB.
DR   GO; GO:0055037; C:recycling endosome; IEA:UniProtKB-SubCell.
DR   GO; GO:0004197; F:cysteine-type endopeptidase activity; IDA:UniProtKB.
DR   GO; GO:0008234; F:cysteine-type peptidase activity; IDA:GeneDB.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0006508; P:proteolysis; IDA:UniProtKB.
DR   InterPro; IPR029030; Caspase-like_dom_sf.
DR   SUPFAM; SSF52129; SSF52129; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Autocatalytic cleavage; Calcium; Endosome; Hydrolase;
KW   Metal-binding; Protease; Reference proteome; Thiol protease; Zymogen.
FT   PROPEP          1..55
FT                   /evidence="ECO:0000269|PubMed:18005666"
FT                   /id="PRO_0000451273"
FT   CHAIN           56..347
FT                   /note="Metacaspase-2"
FT                   /id="PRO_0000451274"
FT   CHAIN           56..268
FT                   /note="Large subunit p20"
FT                   /evidence="ECO:0000269|PubMed:18005666"
FT                   /id="PRO_0000451275"
FT   CHAIN           269..347
FT                   /note="Small subunit p10"
FT                   /evidence="ECO:0000269|PubMed:18005666"
FT                   /id="PRO_0000451276"
FT   REGION          1..70
FT                   /note="Regulates substrate access to the active site"
FT                   /evidence="ECO:0000305|PubMed:22529389"
FT   ACT_SITE        158
FT                   /evidence="ECO:0000250|UniProtKB:Q08601"
FT   ACT_SITE        213
FT                   /evidence="ECO:0000305|PubMed:18005666"
FT   METAL           173
FT                   /note="Calcium"
FT                   /evidence="ECO:0000269|PubMed:22529389,
FT                   ECO:0007744|PDB:4AFP"
FT   METAL           189
FT                   /note="Calcium"
FT                   /evidence="ECO:0000269|PubMed:22529389,
FT                   ECO:0007744|PDB:4AFP"
FT   METAL           190
FT                   /note="Calcium"
FT                   /evidence="ECO:0000269|PubMed:22529389,
FT                   ECO:0007744|PDB:4AFP"
FT   METAL           220
FT                   /note="Calcium"
FT                   /evidence="ECO:0000269|PubMed:22529389,
FT                   ECO:0007744|PDB:4AFP"
FT   SITE            55..56
FT                   /note="Cleavage; by autolysis"
FT                   /evidence="ECO:0000269|PubMed:18005666"
FT   SITE            95
FT                   /note="Important for Arg/Lys-specific substrate
FT                   specificity"
FT                   /evidence="ECO:0000269|PubMed:22529389"
FT   SITE            211
FT                   /note="Important for Arg/Lys-specific substrate
FT                   specificity"
FT                   /evidence="ECO:0000269|PubMed:22529389"
FT   SITE            268
FT                   /note="Cleavage; by autolysis"
FT                   /evidence="ECO:0000269|PubMed:18005666"
FT   MUTAGEN         31
FT                   /note="Y->A: Increases autoprocessing resulting in the
FT                   degradation of the enzyme."
FT                   /evidence="ECO:0000269|PubMed:22529389"
FT   MUTAGEN         55
FT                   /note="K->G: Loss of autoprocessing. Loss of catalytic
FT                   activity towards large protein substrates, no effect on
FT                   catalytic activity towards short oligopeptide substrates,
FT                   reduces affinity of the high affinity Ca(2+) binding site,
FT                   shifts optimum pH for activity towards basic pH; when
FT                   associated with G-268."
FT                   /evidence="ECO:0000269|PubMed:18005666,
FT                   ECO:0000269|PubMed:28089596"
FT   MUTAGEN         92
FT                   /note="C->A: Reduced autoprocessing and 50% loss of
FT                   catalytic activity towards substrates."
FT                   /evidence="ECO:0000269|PubMed:22529389"
FT   MUTAGEN         95
FT                   /note="D->A: Loss of autoprocessing and catalytic activity
FT                   towards substrates."
FT                   /evidence="ECO:0000269|PubMed:22529389"
FT   MUTAGEN         156
FT                   /note="S->A: 3-fold increase in catalytic activity towards
FT                   substrates."
FT                   /evidence="ECO:0000269|PubMed:22529389"
FT   MUTAGEN         189..190
FT                   /note="DD->AA: Loss of autoprocessing and catalytic
FT                   activity towards substrates."
FT                   /evidence="ECO:0000269|PubMed:22529389"
FT   MUTAGEN         211
FT                   /note="D->A: Loss of autoprocessing and catalytic activity
FT                   towards substrates."
FT                   /evidence="ECO:0000269|PubMed:22529389"
FT   MUTAGEN         212
FT                   /note="C->G: Severe loss of catalytic activity."
FT                   /evidence="ECO:0000269|PubMed:18005666"
FT   MUTAGEN         213
FT                   /note="C->G: Complete loss of catalytic activity."
FT                   /evidence="ECO:0000269|PubMed:18005666"
FT   MUTAGEN         268
FT                   /note="K->G: Loss of autoprocessing. Loss of catalytic
FT                   activity towards large protein substrates, no effect on
FT                   catalytic activity towards short oligopeptide substrates,
FT                   reduces affinity of the high affinity Ca(2+) binding site,
FT                   shift optimum pH for activity towards basic pH; when
FT                   associated with G-55."
FT                   /evidence="ECO:0000269|PubMed:18005666,
FT                   ECO:0000269|PubMed:28089596"
FT   TURN            8..10
FT                   /evidence="ECO:0007744|PDB:4AFR"
FT   TURN            17..24
FT                   /evidence="ECO:0007744|PDB:4AF8"
FT   STRAND          31..34
FT                   /evidence="ECO:0007744|PDB:4AFV"
FT   HELIX           47..54
FT                   /evidence="ECO:0007744|PDB:4AF8"
FT   STRAND          73..79
FT                   /evidence="ECO:0007744|PDB:4AF8"
FT   HELIX           92..105
FT                   /evidence="ECO:0007744|PDB:4AF8"
FT   STRAND          111..117
FT                   /evidence="ECO:0007744|PDB:4AF8"
FT   HELIX           131..143
FT                   /evidence="ECO:0007744|PDB:4AF8"
FT   STRAND          150..157
FT                   /evidence="ECO:0007744|PDB:4AF8"
FT   STRAND          159..162
FT                   /evidence="ECO:0007744|PDB:4AF8"
FT   STRAND          173..176
FT                   /evidence="ECO:0007744|PDB:4AF8"
FT   HELIX           181..184
FT                   /evidence="ECO:0007744|PDB:4AF8"
FT   HELIX           189..196
FT                   /evidence="ECO:0007744|PDB:4AF8"
FT   TURN            197..199
FT                   /evidence="ECO:0007744|PDB:4AF8"
FT   STRAND          205..211
FT                   /evidence="ECO:0007744|PDB:4AF8"
FT   STRAND          222..226
FT                   /evidence="ECO:0007744|PDB:4AF8"
FT   STRAND          250..258
FT                   /evidence="ECO:0007744|PDB:4AF8"
FT   STRAND          278..281
FT                   /evidence="ECO:0007744|PDB:4AFV"
FT   HELIX           283..293
FT                   /evidence="ECO:0007744|PDB:4AF8"
FT   HELIX           300..313
FT                   /evidence="ECO:0007744|PDB:4AF8"
FT   STRAND          319..326
FT                   /evidence="ECO:0007744|PDB:4AF8"
FT   STRAND          336..338
FT                   /evidence="ECO:0007744|PDB:4AF8"
SQ   SEQUENCE   347 AA;  37779 MW;  00523E8CCF7B214A CRC64;
     MCSLITQLCD AGQLADYVGL GWLNAVSSQP YLVQALGLQP PPRRVDVDAA FRDAKGLHGH
     QPWVATPLPG QTVRALFIGI NYYGTSAALS GCCNDVKQML ATLQKKGLPI NEAVILVDED
     NFPGRTDQPT RDNIVRYMAW LVKDAKPGDV LFFHYSGHGT QCKSRGDSDE KYDQCIAPVD
     FQKSGCIVDD DIHKLLFSRL PEKVRLTAVF DCCHSGSIMD LPFTYVCSGG EQASGTPHMK
     RIREGNDVLG DVMMISGCAD EQTSADVKNT ATFGTGSTGA GGAATQCITC MLMNNQSLSY
     GKLLIETRDM LKRKGFKQVP QLSASKAIDL DQTFSLTEMF SVDRSIQ
//
